We observed a significant enhancement of Bid cleavage in all prostate cancer cells lines treated with the combination of cisplatin/LA-12 and TRAIL compared to the agents used alone (Fig 2A and S1 Fig). This evidence concerns the gene TNFSF10 and prostate cancer.